ArticleStem cells international2018
Safety of Autologous Cord Blood Cells for Preterms: A Descriptive Study.
Article in Stem cells international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Umbilical cord blood-derived therapy for preterm lung injury: a systematic review and meta-analysis.Stem cells translational medicine · 2024Pooled it
- Stem cell-based interventions for the prevention and treatment of germinal matrix-intraventricular haemorrhage in preterm infants.The Cochrane database of systematic reviews · 2019Pooled it
- A Novel Cellular Therapy for Preterm Complications: Safety Profile of Allogeneic Cord Blood Mononuclear Cells in a Pilot Clinical Study.Stem cells international · 2026Article
- Application of Umbilical Cord Blood for the Clinical Prevention and Treatment of Complications in Preterm Infants(Review).Stem cell reviews and reports · 2026Review
- Promising Preventive Strategies for Intraventricular Hemorrhage in Preterm Neonates: A Critical Review.Journal of clinical medicine · 2025Review
- Umbilical cord blood cell characteristics in very preterm neonates for autologous cell therapy of preterm-associated complications.BMC pediatrics · 2024Article
- Stem cell-based interventions for the prevention and treatment of intraventricular haemorrhage and encephalopathy of prematurity in preterm infants.The Cochrane database of systematic reviews · 2023Review
- Headway and the remaining hurdles of mesenchymal stem cells therapy for bronchopulmonary dysplasia.The clinical respiratory journal · 2022Review
- Rationale for the Use of Cord Blood in Hypoxic-Ischaemic Encephalopathy.Stem cells international · 2022Review
- Article
- Autologous cord blood cell infusion in preterm neonates safely reduces respiratory support duration and potentially preterm complications.Stem cells translational medicine · 2020Article
- Neurovascular effects of umbilical cord blood-derived stem cells in growth-restricted newborn lambs : UCBCs for perinatal brain injury.Stem cell research & therapy · 2020Article
- Use of Autologous Cord Blood Mononuclear Cells Infusion for the Prevention of Bronchopulmonary Dysplasia in Extremely Preterm Neonates: A Study Protocol for a Placebo-Controlled Randomized Multicenter Trial [NCT03053076].Frontiers in pediatrics · 2020Article
- Autologous cord blood in children with cerebral palsy: a review.International journal of molecular sciences · 2019Review
- Feasibility of Umbilical Cord Blood Collection in Neonates at Risk of Brain Damage-A Step Toward Autologous Cell Therapy for a High-risk Population.Cell transplantationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPreterm birth complications are one of the leading causes of death among children under 5 years of age. Despite advances in medical care, many survivors face a lifetime of disability, including mental and physical retardation, and chronic lung disease. More recently, both allogenic and autogenic cord blood cells have been applied in the treatment of neonatal conditions such as hypoxic-ischemic encephalopathy (HIE) and bronchopulmonary dysplasia (BPD).
objectiveTo assess the safety of autologous, volume- and red blood cell- (RBC-) reduced, noncryopreserved umbilical cord blood (UCB) cell infusion to preterm infants.
methodThis study was a phase I, open-label, single-arm, single-center trial to evaluate the safety of autologous, volume- and RBC-reduced, noncryopreserved UCB cell (5 × 10
resultsAfter processing, (22.67 ± 4.05) ml UCB cells in volume, (2.67 ± 2.00) × 10
conclusionsCollection, preparation, and infusion of fresh autologous UCB cells to preterm infants is feasible and safe. Adequately powered randomized controlled studies are needed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.